Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週四收盤下跌約250點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將其視爲其整體投資或交易決策中的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是近期一些值得注意的細價股內幕交易。欲了解更多，請查看 本辛加的內幕交易 平台。
Black Diamond Therapeutics
黑鑽療法
- The Trade: Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) 10% owner BB Biotech AG acquired a total of 400,000 shares an average price of $2.34. To acquire these shares, it cost around $934,080.
- What's Happening: Black Diamond Therapeutics presented dose escalation data demonstrating durable responses in patients with NSCLC from Phase 1 trial of BDTX-1535 at the AACR-NCI-EORTC International Conference.
- What Black Diamond Therapeutics Does: Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies.
- 交易： 黑鑽治療公司 (納斯達克股票代碼：BDTX) 10% 的所有者 BB Biotech AG 共收購40萬股股票 平均價格爲2.34美元。收購這些股票的成本約爲934,080美元。
- 發生了什麼： Black Diamond Therapeutics在AACR-NCI-EORTC國際會議上公佈了劑量遞增數據，顯示了來自 BDTX-1535 一期試驗的非小細胞肺癌患者的持久反應。
- 黑鑽療法的作用： 黑鑽治療公司是一家精準腫瘤醫學公司。它從事小分子、與腫瘤無關的療法的發現和開發。
Bespoke Extracts
定製摘錄
- The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod acquired a total of 3,000 shares at an average price of $0.20. To acquire these shares, it cost around $560.
- What's Happening: The company's stock fell around 5% year-to-date.
- What Bespoke Extracts Does: Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.
- 這筆交易: 定製提取物, Inc. （場外交易代碼：BSPK）首席執行官邁克爾·費恩索德 共收購了3,000股股票 平均價格爲0.20美元。收購這些股票的成本約爲560美元。
- 發生了什麼: 該公司的股票今年迄今下跌了約5％。
- 定製提取物的作用: Bespoke Extracts Inc專注於銷售其專有的特殊配方、優質、大麻衍生的CBD產品系列。
Check This Out: Top 3 Materials Stocks You May Want To Dump This Month
看看這個： 本月你可能想拋售的三大材料股
Vivos
Vivos
- The Trade: Vivos Inc. (OTC:RDGL) CEO and President Micheal Korenko acquired a total of 100,000 shares at an average price of $0.05. The insider spent 5,360 to buy those shares.
- What's Happening: The company's stock declined 22% over the past month.
- What Vivos Does: Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors.
- 這筆交易: Vivos Inc. (OTC: RDGL) 首席執行官兼總裁邁克爾·科連科 共收購了10萬股股票 平均價格爲0.05美元。知情人士花了5,360美元購買了這些股票。
- 發生了什麼：該公司的股票在過去一個月中下跌了22％。
- Vivos 做什麼: Vivos Inc是一家放射腫瘤醫療器械公司。它正在開發RadioGel，這是一種近距離放射治療設備，由針頭注射輸送的高度不溶性顆粒組成，使用水聚合物複合材料，用於對不可切除的實體瘤進行高劑量治療。
Don't forget to check out our premarket coverage here
別忘了在這裏查看我們的上市前報道
譯文內容由第三人軟體翻譯。